• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEB
Click for more information
12.5% 0.9¢

MEDIBIO LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MEB Resignation of Director19/01/18
MEB Appendix 3B16/01/18
MEB Medibio Announces ISO 13485 CertificationPRICE SENSITIVE10/01/18
MEB Medibio & Mayo Clinic collaborate on depression technologyPRICE SENSITIVE14/12/17
MEB US Veterans Affairs joins Medibio FDA study08/12/17
MEB Appendix 3B05/12/17
MEB Results of Meeting30/11/17
MEB Chairman's & CEO Address to Shareholders30/11/17
MEB Appendix 3B14/11/17
MEB Appendix 4G & Corporate Governance Statement13/11/17
MEB Notice of Annual General Meeting/Proxy Form01/11/17
MEB Appendix 4C - quarterlyPRICE SENSITIVE30/10/17
MEB R&D Tax Incentive Refund received25/10/17
MEB Becoming a substantial holder24/10/17
MEB Annual Report to shareholders24/10/17
MEB Disclosure Document - Cleansing Statement23/10/17
MEB Appendix 3B23/10/17
MEB Final Director's Interest Notice13/10/17
MEB Change of Director's Interest Notice13/10/17
MEB Director Resignation13/10/17
MEB MEB completes heavily oversubscribed institutional placementPRICE SENSITIVE13/10/17
MEB Appendix 3B12/10/17
MEB Trading HaltPRICE SENSITIVE11/10/17
MEB Response to ASX QueryPRICE SENSITIVE11/10/17
MEB Medibio enters into an Agreement with Otsuka PharmaceuticalPRICE SENSITIVE09/10/17
MEB Change of Directors Interest Notice04/10/17
MEB Medibio enters agreement with Mayo ClincPRICE SENSITIVE04/10/17
MEB Full Year Statutory Accounts29/09/17
MEB Appendix 3B29/09/17
MEB Results of Meeting11/09/17
MEB Medibio Investment Presentation Update11/09/17
MEB Preliminary Final ReportPRICE SENSITIVE01/09/17
MEB Change of Director's Interest Notice31/08/17
MEB Appendix 3B29/08/17
MEB Medibio initiates confirmatory studyPRICE SENSITIVE21/08/17
MEB Notice of General Meeting/Proxy Form11/08/17
MEB Change of Director's Interest Notice03/08/17
MEB Medibio announces positive clinical study resultsPRICE SENSITIVE02/08/17
MEB Quarterly ASX Update and CashflowsPRICE SENSITIVE27/07/17
MEB Change of Director's Interest Notice26/07/17
MEB Unmarketable Parcel Share Sale Facility21/07/17
MEB Medibio presentation at Bioshares Biotech Summit 201720/07/17
MEB Initial Director's Interest Notice20/07/17
MEB Adam Darkins, Telehealth icon appointed to Medibio board19/07/17
MEB Initial Director's Interest Notice06/07/17
MEB Ceasing to be a substantial holder06/07/17
MEB Mental Healthcare Advocate Patrick Kennedy appointed to Boar04/07/17
MEB Scientific breakthrough on objective diagnosis of PTSDPRICE SENSITIVE26/06/17
MEB Initial Director's Interest Notice09/06/17
MEB Independent researchers present first data validating MEBPRICE SENSITIVE08/06/17
MEB MEB begins trading on OTCQB under Ticker Symbol MDBIF06/06/17
MEB Investor Presentation for US roadshow05/06/17
MEB Michael Phelps Appointed to Medibio Board of Directors05/06/17
MEB Signed second agreement for WellnessPRICE SENSITIVE17/05/17
MEB MEB Signs Strategic Joint Development Agreement with Mayo ClPRICE SENSITIVE10/05/17
MEB Quarterly ASX Update and CashflowPRICE SENSITIVE27/04/17
MEB Medibio appoints experienced US based med-tech CFO20/04/17
MEB Change of Director's Interest Notice20/04/17
MEB MEB enters fully funded Paediatric mental illness diagnosticPRICE SENSITIVE10/04/17
MEB Conversion of Options to Partly Paid sharesPRICE SENSITIVE05/04/17
MEB Change of Director's Interest Notice05/04/17
MEB Appendix 3B - restatement of 27 March lodgement29/03/17
MEB Appendix 3B27/03/17
MEB Investor Presentation Deck20/03/17
MEB Company UpdatePRICE SENSITIVE20/03/17
MEB Change of Director's Interest Notice07/03/17
MEB Appendix 3B07/03/17
MEB Half Yearly Report and AccountsPRICE SENSITIVE28/02/17
MEB Initial Director's Interest Notice21/02/17
MEB MEB appoints US med-tech veteran as CEO & Managing DirectorPRICE SENSITIVE16/02/17
MEB Change in substantial holding08/02/17
MEB Appendix 3B03/02/17
MEB Initial Director's Interest Notice01/02/17
MEB Appointment of Non Executive Director & Advisory Board Chang01/02/17
MEB Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
MEB Early Redemption of Convertible NotePRICE SENSITIVE30/01/17
MEB Partnership with leading US University on PTSDPRICE SENSITIVE25/01/17
MEB Change in substantial holding05/01/17
MEB Medibio Newsletter29/12/16
MEB Details of Company Address - Registered Office21/12/16
MEB Excellent performance in the pilot phase of US ValidationPRICE SENSITIVE21/12/16
MEB Change in substantial holding08/12/16
MEB Becoming a substantial holder05/12/16
MEB Disclosure Document - Notice under Section 708A05/12/16
MEB Appendix 3B05/12/16
MEB Results of Meeting29/11/16
MEB Medibio AGM Presentation29/11/16
MEB Disclosure Document - Section 708A (5) Notice25/11/16
MEB Appendix 3B25/11/16
MEB Medibio enters into binding agreement with MedtronicPRICE SENSITIVE24/11/16
MEB Capital raising of $13.5million to accelerate growthPRICE SENSITIVE18/11/16
MEB Trading HaltPRICE SENSITIVE15/11/16
MEB Appendix 3B-MEB.AX 03/11/16
MEB Appendix 3B03/11/16
MEB Outstanding 86% accuracy in 889 person Ottawa Uni study-MEB.AX PRICE SENSITIVE02/11/16
MEB Quarterly Activities Report-MEB.AX PRICE SENSITIVE31/10/16
MEB Quarterly Cashflow Report-MEB.AX PRICE SENSITIVE31/10/16
MEB Medibio newsletter to Shareholders-MEB.AX 28/10/16
MEB Notice of Annual General Meeting/Proxy Form-MEB.AX 28/10/16
MEB Appendix 3B-MEB.AX 28/10/16
MEB Resignation of Director
19/01/18
MEB Appendix 3B
16/01/18
MEB Medibio Announces ISO 13485 Certification
10/01/18PRICE SENSITIVE
MEB Medibio & Mayo Clinic collaborate on depression technology
14/12/17PRICE SENSITIVE
MEB US Veterans Affairs joins Medibio FDA study
08/12/17
MEB Appendix 3B
05/12/17
MEB Results of Meeting
30/11/17
MEB Chairman's & CEO Address to Shareholders
30/11/17
MEB Appendix 3B
14/11/17
MEB Appendix 4G & Corporate Governance Statement
13/11/17
MEB Notice of Annual General Meeting/Proxy Form
01/11/17
MEB Appendix 4C - quarterly
30/10/17PRICE SENSITIVE
MEB R&D Tax Incentive Refund received
25/10/17
MEB Becoming a substantial holder
24/10/17
MEB Annual Report to shareholders
24/10/17
MEB Disclosure Document - Cleansing Statement
23/10/17
MEB Appendix 3B
23/10/17
MEB Final Director's Interest Notice
13/10/17
MEB Change of Director's Interest Notice
13/10/17
MEB Director Resignation
13/10/17
MEB MEB completes heavily oversubscribed institutional placement
13/10/17PRICE SENSITIVE
MEB Appendix 3B
12/10/17
MEB Trading Halt
11/10/17PRICE SENSITIVE
MEB Response to ASX Query
11/10/17PRICE SENSITIVE
MEB Medibio enters into an Agreement with Otsuka Pharmaceutical
09/10/17PRICE SENSITIVE
MEB Change of Directors Interest Notice
04/10/17
MEB Medibio enters agreement with Mayo Clinc
04/10/17PRICE SENSITIVE
MEB Full Year Statutory Accounts
29/09/17
MEB Appendix 3B
29/09/17
MEB Results of Meeting
11/09/17
MEB Medibio Investment Presentation Update
11/09/17
MEB Preliminary Final Report
01/09/17PRICE SENSITIVE
MEB Change of Director's Interest Notice
31/08/17
MEB Appendix 3B
29/08/17
MEB Medibio initiates confirmatory study
21/08/17PRICE SENSITIVE
MEB Notice of General Meeting/Proxy Form
11/08/17
MEB Change of Director's Interest Notice
03/08/17
MEB Medibio announces positive clinical study results
02/08/17PRICE SENSITIVE
MEB Quarterly ASX Update and Cashflows
27/07/17PRICE SENSITIVE
MEB Change of Director's Interest Notice
26/07/17
MEB Unmarketable Parcel Share Sale Facility
21/07/17
MEB Medibio presentation at Bioshares Biotech Summit 2017
20/07/17
MEB Initial Director's Interest Notice
20/07/17
MEB Adam Darkins, Telehealth icon appointed to Medibio board
19/07/17
MEB Initial Director's Interest Notice
06/07/17
MEB Ceasing to be a substantial holder
06/07/17
MEB Mental Healthcare Advocate Patrick Kennedy appointed to Boar
04/07/17
MEB Scientific breakthrough on objective diagnosis of PTSD
26/06/17PRICE SENSITIVE
MEB Initial Director's Interest Notice
09/06/17
MEB Independent researchers present first data validating MEB
08/06/17PRICE SENSITIVE
MEB MEB begins trading on OTCQB under Ticker Symbol MDBIF
06/06/17
MEB Investor Presentation for US roadshow
05/06/17
MEB Michael Phelps Appointed to Medibio Board of Directors
05/06/17
MEB Signed second agreement for Wellness
17/05/17PRICE SENSITIVE
MEB MEB Signs Strategic Joint Development Agreement with Mayo Cl
10/05/17PRICE SENSITIVE
MEB Quarterly ASX Update and Cashflow
27/04/17PRICE SENSITIVE
MEB Medibio appoints experienced US based med-tech CFO
20/04/17
MEB Change of Director's Interest Notice
20/04/17
MEB MEB enters fully funded Paediatric mental illness diagnostic
10/04/17PRICE SENSITIVE
MEB Conversion of Options to Partly Paid shares
05/04/17PRICE SENSITIVE
MEB Change of Director's Interest Notice
05/04/17
MEB Appendix 3B - restatement of 27 March lodgement
29/03/17
MEB Appendix 3B
27/03/17
MEB Investor Presentation Deck
20/03/17
MEB Company Update
20/03/17PRICE SENSITIVE
MEB Change of Director's Interest Notice
07/03/17
MEB Appendix 3B
07/03/17
MEB Half Yearly Report and Accounts
28/02/17PRICE SENSITIVE
MEB Initial Director's Interest Notice
21/02/17
MEB MEB appoints US med-tech veteran as CEO & Managing Director
16/02/17PRICE SENSITIVE
MEB Change in substantial holding
08/02/17
MEB Appendix 3B
03/02/17
MEB Initial Director's Interest Notice
01/02/17
MEB Appointment of Non Executive Director & Advisory Board Chang
01/02/17
MEB Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
MEB Early Redemption of Convertible Note
30/01/17PRICE SENSITIVE
MEB Partnership with leading US University on PTSD
25/01/17PRICE SENSITIVE
MEB Change in substantial holding
05/01/17
MEB Medibio Newsletter
29/12/16
MEB Details of Company Address - Registered Office
21/12/16
MEB Excellent performance in the pilot phase of US Validation
21/12/16PRICE SENSITIVE
MEB Change in substantial holding
08/12/16
MEB Becoming a substantial holder
05/12/16
MEB Disclosure Document - Notice under Section 708A
05/12/16
MEB Appendix 3B
05/12/16
MEB Results of Meeting
29/11/16
MEB Medibio AGM Presentation
29/11/16
MEB Disclosure Document - Section 708A (5) Notice
25/11/16
MEB Appendix 3B
25/11/16
MEB Medibio enters into binding agreement with Medtronic
24/11/16PRICE SENSITIVE
MEB Capital raising of $13.5million to accelerate growth
18/11/16PRICE SENSITIVE
MEB Trading Halt
15/11/16PRICE SENSITIVE
MEB Appendix 3B-MEB.AX
03/11/16
MEB Appendix 3B
03/11/16
MEB Outstanding 86% accuracy in 889 person Ottawa Uni study-MEB.AX
02/11/16PRICE SENSITIVE
MEB Quarterly Activities Report-MEB.AX
31/10/16PRICE SENSITIVE
MEB Quarterly Cashflow Report-MEB.AX
31/10/16PRICE SENSITIVE
MEB Medibio newsletter to Shareholders-MEB.AX
28/10/16
MEB Notice of Annual General Meeting/Proxy Form-MEB.AX
28/10/16
MEB Appendix 3B-MEB.AX
28/10/16
refresh Created with Sketch. REFRESH
 

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia New Zealand’s Reserve Bank has taken a bold step, slashing rates by 50 basis points to 4.25% @ its third cut in just four months. Meanwhile, the Reserve Bank of Australia holds firm at 4.35%, its highest rate in over a decade.This stark policy divergence highlights contrasting glo...
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.